Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Zykadia (Ceritinib),ZykadiaStudy001,2022,USA,MDV,350,62,45,55,27.5,60,75,12,15,30,40,15,40,30,20,10,20,35,45,18,7,3,9,4,25,55,40,Cisplatin + Pemetrexed,Carboplatin + Paclitaxel,Vinorelbine + Cisplatin,Docetaxel + Carboplatin,0,0,0,35,65,50,15,45,40,60,2
Zykadia (Ceritinib),ZykadiaStudy002,2023,Germany,Claim Database,420,68,48,52,26.8,55,70,10,12,28,42,18,38,32,18,12,18,32,50,20,8,4,10,5,22,58,38,Carboplatin + Pemetrexed,Cisplatin + Gemcitabine,Paclitaxel + Carboplatin,Gemcitabine + Cisplatin,0,0,0,40,70,55,10,50,40,70,3
Zykadia (Ceritinib),ZykadiaStudy003,2023,Japan,MDV,280,70,42,58,25.5,45,80,8,18,32,35,15,42,28,15,15,22,38,40,15,6,2,8,3,28,52,42,Pemetrexed + Carboplatin,Gemcitabine + Cisplatin,Cisplatin + Vinorelbine,Carboplatin + Docetaxel,0,0,0,30,60,45,20,40,40,55,2.5
